GSK steps up share buyback as fresh annual report spells out CEO Luke Miels’ 2026 priorities

Johnson & Johnson slipped roughly 0.7% Wednesday, even as the company announced its lupus drug candidate nipocalimab received Fast Track designation from the U.S. FDA. Shares traded at $245.07, down $1.68 in the afternoon session.

Johnson & Johnson is weighing a sale of its DePuy Synthes orthopedics division that could fetch more than $20 billion, according to a source familiar with the situation, speaking to Reuters on Thursday. The company hasn’t commented yet. This potential sale marks a pivot from J&J’s previously outlined plan to spin off DePuy Synthes over the next 18 to 24 months. CFO Joe Wolk previously indicated no major updates would come before mid-2026. DePuy pulled in $9.3 billion in sales for 2025 and has faced thousands of hip implant lawsuits, Reuters noted.